Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for resear
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance. Subject to
IDbyDNA announces a global strategic partnership with Illumina to bring next-generation sequencing based workflows to the global microbiology market.
Illumina reported earnings per share of $1. 7 on revenue of $907M, the consensus between analysts was $1.58 per share on revenue of $946M.
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Fourth quarter 2019 results: Revenue
ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests
/PRNewswire/ -- ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next. . .
Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. . . .
You pay a high price for a company with near monopoly like Illumina. ILMN stock has 70% market share, but Its valuation is too high.
Illumina reported earnings per share of $1. 93 on revenue of $838M, the consensus between analysts was $1.4 per share on revenue of $871M.